{"nctId":"NCT01313624","briefTitle":"Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","startDateStruct":{"date":"2011-04"},"conditions":["Bronchiectasis"],"count":266,"armGroups":[{"label":"AZLI-AZLI","type":"EXPERIMENTAL","interventionNames":["Drug: AZLI"]},{"label":"Placebo-AZLI","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AZLI","Drug: Placebo"]}],"interventions":[{"name":"AZLI","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/Female 18 years or older with non-CF bronchiectasis\n* Chronic sputum production on most days\n* Positive sputum culture for gram-negative organisms\n* Must have met lung function requirements\n\nExclusion Criteria:\n\n* History of CF\n* Hospitalized within 14 days prior to joining the study\n* Previous exposure to AZLI\n* Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study\n* Must have met liver and kidney function requirements\n* Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed)\n* Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment\n* Other serious medical conditions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in QOL-B Respiratory Symptoms Score at Day 28","description":"The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"21.37"},{"groupId":"OG001","value":"5.7","spread":"13.62"}]}]}]},{"type":"SECONDARY","title":"Change in QOL-B Respiratory Symptoms Score at Day 84","description":"The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"21.67"},{"groupId":"OG001","value":"4.7","spread":"17.24"}]}]}]},{"type":"SECONDARY","title":"Time to Protocol-Defined Exacerbation (PDE)","description":"Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.\n\n* Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough\n* Minor Criteria: fever (\\> 38ยบ C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased \\> 10% from baseline; new or increased hemoptysis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":134},"commonTop":["Cough","Dyspnoea","Sputum Increased","Fatigue","Sputum discoloured"]}}}